Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

59352-U21

Supelco

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 5 cm × 2.1 mm, HPLC Column

Sinónimos:

C8 Reversed-Phase Chromatography Column

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Columna para HPLC Discovery® C8, 5 μm particle size, L × I.D. 5 cm × 2.1 mm

material

stainless steel column

Quality Level

100

agency

suitable for USP L7

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

7.5% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

5 cm × 2.1 mm

surface area

200 m2/g

surface coverage

3.4 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical base material
fully porous particle

matrix active group

C8 (octyl) phase

particle size

5 μm

pore size

180 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application


  • UHPLC-MS/MS method for chiral separation of 3-hydroxy fatty acids: Highlighting the adaptability of the Discovery® C8 column, this paper details its application in a sophisticated chiral separation method, underscoring its importance in clinical diagnostics and research (Fu et al., 2023).

Features and Benefits

Características de la Discovery® C8:
• Selectividad y retención clásica C18
• Excelente forma del pico
• Estable, separaciones CL/EM (LC/MS) sin sangrado
• Similar selectividad que la C18, con menor retención hidrófoba.

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Referencia del producto
Descripción
Precios

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
290297-02
290297-01
290296-02
290296-01
290155-02

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

G L Bundy et al.
The Journal of biological chemistry, 261(2), 747-751 (1986-01-15)
The gorgonian coral Pseudoplexaura porosa contains a lipoxygenase capable of converting exogenous arachidonic acid into (8R)-8-hydroperoxy-5,9,11,14-eicosatetraenoic acid. The (8R)- (or 8-L-) configuration in this product, opposite to that observed in previously reported 8-lipoxygenase products, was determined unambiguously by comparison of
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
Simeon Grazio et al.
Clinical and experimental rheumatology, 31(5), 665-671 (2013-06-07)
Using proteomic approach in this study, we sought to identify proteins with heparin affinity associated with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and non-inflammatory arthritis (NIA). Plasma samples from adult RA, PsA and NIA patients, 20 of each, were collected.
M Q Zhang et al.
Die Pharmazie, 46(10), 687-700 (1991-10-01)
The rapid growth in the quinolone research changed the whole face of the previous SAR concepts. So far structural modifications at all positions of the quinolone nucleus except the 4-oxo group have successfully lead to the discovery of potent antimicrobial
J Reniers et al.
European journal of medicinal chemistry, 46(12), 6104-6111 (2011-10-25)
Previous studies on 5H-indeno[1,2-c]pyridazin-5-one derivatives as inhibitors of MAO-B revealed that it was possible to increase the MAO-B inhibitory potency of 5H-indeno[1,2-c]pyridazin-5-ones by substituting the central heterocycle in the 3-position or C-8 with lipophilic groups which occupy the substrate cavity
Ver todos los artículos relacionados

Contenido relacionado

Discovery C18 and C8 HPLC Columns

Discovery C18 and C8 HPLC Columns products offered

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico